维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

1篇 您的检索式：作者名="Guiwang Pan"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	CD19-targeted chimeric antigen receptor-modified T cells induce remission in patients with relapsed acute B lymphoblastic leukemia after umbilical cord blood transplantation显示文摘To the Editor:Umbilical cord blood transplant(UCBT)serves as an alternative option for treating patients with B cell acute lymphoblastic leukemia(ALL),in the absence of a compatible donor.However,disease recurrence presents a difficult challenge.Chimeric antigen receptor(CAR)-T cell therapy is a promising approach for treating patients with relapsed/refractory ALL.Among the intensive investigations of infusion of CAR-T cells after transplant,few focus on patients who were administered CAR-T therapy after they relapsed subsequently to UCBT.Here,we report the response rate,toxicity,and survival of CD19 CAR-T cells administered to 10 children and young adults with relapsed acute B lymphoblastic leukemia(B-ALL)after UCBT.Between April 2018 and September 2019,11 patients with relapsed B-ALL after UCBT were enrolled,including three females and eight males,the median age was 10 years(range 7-22 years)and median weight was 35.0 kg(range 21.0-72.0 kg).Patient 10 was excluded because of unsuccessful cell culture.	Qianwen Xu Hui Xu Lei Xue Min Wang Guiwang Pan Xuhan Zhang Kaidi Song Wen Yao Xiang Wan Juan Tong Huilan Liu Hanying Xu Xin Liu Xiaoyu Zhu Zimin Sun Lin Yang Xingbing Wang	2022	Chinese Medical Journal2022，，1：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费